Natera Launches Zenith Genomics To Expand Rare Disease Testing Story

Simply Wall St.03-14 01:40

Natera (NasdaqGS:NTRA) has launched Zenith Genomics, a next generation whole genome sequencing assay for rare disease detection. The assay is being introduced in partnership with MyOme, with exclusive...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619731112?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-14 01:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619731112","market":"nz","top_or_hot":-1,"title":"Natera Launches Zenith Genomics To Expand Rare Disease Testing Story","media":"Simply Wall St.","content":"<div>\n<p>Natera (NasdaqGS:NTRA) has launched Zenith Genomics, a next generation whole genome sequencing assay for rare disease detection. The assay is being introduced in partnership with MyOme, with exclusive...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-launches-zenith-genomics-to-expand-rare-disease-testi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera Launches Zenith Genomics To Expand Rare Disease Testing Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera Launches Zenith Genomics To Expand Rare Disease Testing Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-14 01:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-launches-zenith-genomics-to-expand-rare-disease-testi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Natera (NasdaqGS:NTRA) has launched Zenith Genomics, a next generation whole genome sequencing assay for rare disease detection. The assay is being introduced in partnership with MyOme, with exclusive...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-launches-zenith-genomics-to-expand-rare-disease-testi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0963586101.USD","symbol_name":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-launches-zenith-genomics-to-expand-rare-disease-testi","article_id":"2619731112","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/natera-launches-zenith-genomics-to-expand-rare-disease-testi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619731112","pubTimestamp":1773423604,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Natera (NasdaqGS:NTRA) has launched Zenith Genomics, a next generation whole genome sequencing assay for rare disease detection.\nThe assay is being introduced in partnership with MyOme, with exclusive collaboration around genome wide rare disease diagnostics.\nZenith Genomics integrates advanced methylation analysis with DNA sequencing to address difficult diagnostic questions in rare conditions.\nThe launch and supporting data are being presented at a leading medical genetics conference,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4139":"生物科技","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","NTRA":"Natera, Inc.","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC"},"translate_title":"Natera推出Zenith Genomics拓展罕见病检测故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5},"content_text":"Natera (NasdaqGS:NTRA) has launched Zenith Genomics, a next generation whole genome sequencing assay for rare disease detection. The assay is being introduced in partnership with MyOme, with exclusive collaboration around genome wide rare disease diagnostics. Zenith Genomics integrates advanced methylation analysis with DNA sequencing to address difficult diagnostic questions in rare conditions. The launch and supporting data are being presented at a leading medical genetics conference, targeting clinicians focused on complex hereditary disease.  Natera is already known for its genetic testing portfolio across oncology, women’s health and organ health. Zenith Genomics adds a whole genome rare disease offering to that mix. The assay uses both DNA and epigenetic information, which is designed to help clinicians address cases where standard sequencing has not provided clear answers. For investors, it represents another technology pillar tied to specialist clinical use. The MyOme partnership and planned electronic medical record integration point to a model that aims to fit into everyday clinical workflows rather than remaining confined to research settings. As Natera references rapid expansion of actionable disease targets, you may want to watch how quickly the test menu develops and how adoption progresses among geneticists and rare disease centers. Stay updated on the most important news stories for Natera by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Natera. NasdaqGS:NTRA Earnings & Revenue Growth as at Mar 2026 3 things going right for Natera that this headline doesn't cover. This launch is really about Natera trying to broaden its role in high complexity genomics by pairing MyOme’s multi omic platform with its own commercial reach. Zenith genomics sits alongside Signatera and the women’s and organ health tests, giving the company another use case where deep sequencing and interpretation matter. The focus on long read sequencing, methylation signatures and whole genome coverage speaks directly to rare disease cases where standard panels have not delivered clear diagnoses, which is a pain point for clinicians and health systems facing high rare disease costs. AdvertisementHow This Fits Into The Natera Narrative  Zenith supports the existing narrative that new product launches and AI oriented workflows can expand Natera’s footprint in personalized medicine and help justify its investment in genomics infrastructure. The collaboration with MyOme could also stretch resources, as Natera is already funding trials and commercialization in oncology and organ health, so investors may want to watch how operating spend tracks against new revenue sources. The rare disease whole genome focus and integrated methylation readout are not front and center in many oncology heavy narratives, so the potential role of this business line may be underappreciated in some storylines.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for Natera to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Integrating a premium genome test into routine care depends on payer policies for comprehensive sequencing, so any pushback on reimbursement could limit volume despite clinical interest. ⚠️ Competition from other genomics players such as Invitae and GeneDx, and from broader whole genome platforms at companies like Illumina’s partners, may keep pricing and margins under pressure in rare disease testing. 🎁 If Zenith shortens diagnostic timelines for complex conditions, it could strengthen Natera’s relationships with geneticists and tertiary centers, supporting cross selling of its broader test menu. 🎁 Automatic methylation analysis on eligible exome and genome orders from early Q2 2026 may increase test utility for clinicians without adding workflow friction, which can be a practical advantage when health systems standardize vendors.  What To Watch Going Forward You may want to track a few things from here. First, how quickly Zenith is adopted across Natera’s existing electronic medical record integrations and whether ordering becomes routine at major rare disease centers. Second, watch for any updates on payer coverage criteria for whole genome and methylation supported testing, since those policies will influence test economics. Finally, compare Natera’s rare disease progress with updates from peers like Invitae and GeneDx to gauge how competitive its offering appears in terms of clinical utility and workflow. To ensure you're always in the loop on how the latest news impacts the investment narrative for Natera, head to the\ncommunity page for Natera to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619731112","isCrawlerRequest":true}